• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

血清阴性重症肌无力中肌肉特异性激酶(MuSK)抗体的检测与特征分析

Detection and characterization of MuSK antibodies in seronegative myasthenia gravis.

作者信息

McConville John, Farrugia Maria Elena, Beeson David, Kishore Uday, Metcalfe Richard, Newsom-Davis John, Vincent Angela

机构信息

Weatherall Institute of Molecular Medicine and Department of Clinical Neurology, Oxford, UK.

出版信息

Ann Neurol. 2004 Apr;55(4):580-4. doi: 10.1002/ana.20061.

DOI:10.1002/ana.20061
PMID:15048899
Abstract

Antibodies to rat muscle specific kinase, MuSK, have recently been identified in some generalized "seronegative" myasthenia gravis (SNMG) patients, who are often females with marked bulbar symptoms. Using immunoprecipitation of (125)I-labelled-human MuSK, 27 of 66 (41%) seronegative patients were positive, but 18 ocular SNMG patients, 105 AChR antibody positive MG patients, and 108 controls were negative. The antibodies are of high affinity (Kds around 100 pM) with titers between 1 and 200 nM. They bind to the extracellular Ig-like domains of soluble or native MuSK. Surprisingly they are predominantly in the IgG4 subclass. MuSK-antibody associated MG may be different in etiological and pathological mechanisms.

摘要

最近在一些全身性“血清阴性”重症肌无力(SNMG)患者中发现了抗大鼠肌肉特异性激酶(MuSK)抗体,这些患者通常为有明显延髓症状的女性。通过对(125)I标记的人MuSK进行免疫沉淀,66例血清阴性患者中有27例(41%)呈阳性,但18例眼肌型SNMG患者、105例乙酰胆碱受体(AChR)抗体阳性的重症肌无力患者及108例对照均为阴性。这些抗体具有高亲和力(解离常数约为100 pM),滴度在1至200 nM之间。它们与可溶性或天然MuSK的细胞外免疫球蛋白样结构域结合。令人惊讶的是,它们主要属于IgG4亚类。MuSK抗体相关的重症肌无力在病因和病理机制上可能有所不同。

相似文献

1
Detection and characterization of MuSK antibodies in seronegative myasthenia gravis.血清阴性重症肌无力中肌肉特异性激酶(MuSK)抗体的检测与特征分析
Ann Neurol. 2004 Apr;55(4):580-4. doi: 10.1002/ana.20061.
2
AChR phosphorylation and indirect inhibition of AChR function in seronegative MG.血清阴性重症肌无力中乙酰胆碱受体磷酸化及对乙酰胆碱受体功能的间接抑制
Neurology. 2002 Dec 10;59(11):1682-8. doi: 10.1212/01.wnl.0000041625.41937.ff.
3
IgG1 antibodies to acetylcholine receptors in 'seronegative' myasthenia gravis.“血清阴性”重症肌无力中抗乙酰胆碱受体的IgG1抗体
Brain. 2008 Jul;131(Pt 7):1940-52. doi: 10.1093/brain/awn092. Epub 2008 May 31.
4
AChR myasthenia gravis switching to MuSK or double antibody positive myasthenia gravis in two children and literature review.两例儿童乙酰胆碱受体抗体阳性重症肌无力向抗缪勒管激素抗体或双抗体阳性重症肌无力转换及文献复习
Neuromuscul Disord. 2020 Jul;30(7):534-538. doi: 10.1016/j.nmd.2020.03.012. Epub 2020 Apr 13.
5
Cholinergic hyperactivity in patients with myasthenia gravis with MuSK antibodies: A neurophysiological study.重症肌无力伴 MuSK 抗体患者的胆碱能活性亢进:一项神经生理学研究。
Clin Neurophysiol. 2021 Aug;132(8):1845-1849. doi: 10.1016/j.clinph.2021.04.019. Epub 2021 Jun 1.
6
["Seronegative" myasthenia with antibodies against muscle-specific tyrosine-kinase].伴有抗肌肉特异性酪氨酸激酶抗体的“血清阴性”重症肌无力
Nervenarzt. 2004 Apr;75(4):362-7. doi: 10.1007/s00115-003-1672-5.
7
Myopathy in Childhood Muscle-Specific Kinase Myasthenia Gravis.儿童期肌肉特异性激酶重症肌无力的肌病
Pediatr Neurol. 2016 Dec;65:90-92. doi: 10.1016/j.pediatrneurol.2016.08.005. Epub 2016 Aug 20.
8
MuSK antibody-positive, seronegative myasthenia gravis in Korea.韩国的抗肌肉特异性激酶(MuSK)抗体阳性、血清阴性重症肌无力
J Clin Neurosci. 2006 Apr;13(3):353-5. doi: 10.1016/j.jocn.2005.04.028. Epub 2006 Mar 20.
9
Anti-AChR, MuSK, and LRP4 antibodies coexistence: A rare and distinct subtype of myasthenia gravis from Indian subcontinent.乙酰胆碱受体抗体、肌肉特异性酪氨酸激酶抗体和低密度脂蛋白受体相关蛋白 4 抗体共存:来自印度次大陆的一种罕见且独特的重症肌无力亚型。
Clin Chim Acta. 2018 Nov;486:34-35. doi: 10.1016/j.cca.2018.07.011. Epub 2018 Jul 10.
10
Seronegative myasthenia gravis.血清阴性重症肌无力
Semin Neurol. 2004 Mar;24(1):125-33. doi: 10.1055/s-2004-829589.

引用本文的文献

1
MuSK cysteine-rich domain antibodies are pathogenic in a mouse model of autoimmune myasthenia gravis.肌肉特异性激酶富含半胱氨酸结构域抗体在自身免疫性重症肌无力小鼠模型中具有致病性。
J Clin Invest. 2025 Jun 12;135(15). doi: 10.1172/JCI173308. eCollection 2025 Aug 1.
2
Efficacy of MLN9708 (ixazomib) in experimental autoimmune myasthenia gravis and in anti-AChR producing primary thymic cell cultures from myasthenia gravis patients.MLN9708(伊沙佐米)在实验性自身免疫性重症肌无力及重症肌无力患者产生抗乙酰胆碱受体的原发性胸腺细胞培养物中的疗效。
Front Immunol. 2025 May 15;16:1521432. doi: 10.3389/fimmu.2025.1521432. eCollection 2025.
3
Real-World Experience with FcRn Inhibitors Efgartigimod and Rozanolixizumab in Myasthenia Gravis: Administration in Multiple Cycles and Transition from Intravenous to Subcutaneous Formulation.
FcRn抑制剂艾加莫德和罗扎诺利单抗治疗重症肌无力的真实世界经验:多周期给药及从静脉制剂转换为皮下制剂
Neurol Ther. 2025 Jun;14(3):977-988. doi: 10.1007/s40120-025-00748-4. Epub 2025 Apr 21.
4
Long-Term Swallowing Rehabilitation for Muscle-Specific Tyrosine Kinase Antibody-Positive Myasthenia Gravis: A Case Report.肌肉特异性酪氨酸激酶抗体阳性重症肌无力的长期吞咽康复:一例报告
Cureus. 2025 Mar 13;17(3):e80544. doi: 10.7759/cureus.80544. eCollection 2025 Mar.
5
Myasthenia gravis in 2025: five new things and four hopes for the future.2025年的重症肌无力:五件新事与对未来的四点期望。
J Neurol. 2025 Feb 22;272(3):226. doi: 10.1007/s00415-025-12922-7.
6
Patient-specific therapeutic benefit of MuSK agonist antibody ARGX-119 in MuSK myasthenia gravis passive transfer models.在MuSK重症肌无力被动转移模型中,MuSK激动剂抗体ARGX-119对特定患者的治疗益处。
iScience. 2024 Dec 21;28(2):111684. doi: 10.1016/j.isci.2024.111684. eCollection 2025 Feb 21.
7
A clinical perspective on muscle specific kinase antibody positive myasthenia gravis.肌肉特异性激酶抗体阳性重症肌无力的临床视角
Front Immunol. 2024 Dec 5;15:1502480. doi: 10.3389/fimmu.2024.1502480. eCollection 2024.
8
Advances in B Cell Targeting for Treating Muscle-Specific Tyrosine Kinase-Associated Myasthenia Gravis.治疗肌肉特异性酪氨酸激酶相关重症肌无力的B细胞靶向治疗进展
Immunotargets Ther. 2024 Dec 11;13:707-720. doi: 10.2147/ITT.S492062. eCollection 2024.
9
Isolated Respiratory Failure as the Presenting Symptom of Muscle-Specific Kinase Myasthenia Gravis: A Case Report and Literature Review.以孤立性呼吸衰竭为首发症状的肌肉特异性激酶型重症肌无力:一例报告及文献复习
Case Rep Neurol. 2024 Aug 14;16(1):233-241. doi: 10.1159/000540916. eCollection 2024 Jan-Dec.
10
Antibodies in neurological diseases: Established, emerging, explorative.神经疾病中的抗体:已确立的、新出现的、探索性的。
Immunol Rev. 2024 Nov;328(1):283-299. doi: 10.1111/imr.13405. Epub 2024 Oct 1.